Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Pharmacovigilance Europe 2025

This conference offers a unique opportunity to hear leading pioneers from the pharma and biotech industries share the latest cutting-edge insights. Attendees will be able [...]

Go to Top